BRPI0909768A2 - composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto - Google Patents

composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto

Info

Publication number: BRPI0909768A2
Authority: BR; Brazil
Prior art keywords: adrenoceptor; compound; disease; treating; preventing
Prior art date: 2008-04-04

Application number

BRPI0909768A

Other languages

English (en)

Inventor

Bing Li

Cheng Zhu

Chris R Moyes

Dong-Ming Shen

Gregori J Morriello

Ihor E Kopka

Lehua Chang

Liping Wang

Nam Fung Kar

Richard Berger

Scott D Edmondson

Sookhee Nicole Ha

Stephen D Goble

Original Assignee

Merck Sharp & Dohme

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-04

Filing date

2009-04-02

Publication date

2015-10-06

2009-04-02 Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme

2015-10-06 Publication of BRPI0909768A2 publication Critical patent/BRPI0909768A2/pt

2019-01-15 Publication of BRPI0909768B1 publication Critical patent/BRPI0909768B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyrrole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)

BRPI0909768-6A 2008-04-04 2009-04-02 composto, composição farmacêutica, e, uso de um composto BRPI0909768B1 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US12306308P	2008-04-04	2008-04-04
US61/123,063		2008-04-04
US20604309P	2009-01-27	2009-01-27
US61/206,043		2009-01-27
PCT/US2009/039249 WO2009124166A1 (en)	2008-04-04	2009-04-02	Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists

Publications (2)

Publication Number	Publication Date
BRPI0909768A2 true BRPI0909768A2 (pt)	2015-10-06
BRPI0909768B1 BRPI0909768B1 (pt)	2019-01-15

Family

ID=40671093

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0909768-6A BRPI0909768B1 (pt)	2008-04-04	2009-04-02	composto, composição farmacêutica, e, uso de um composto

Country Status (41)

Country	Link
US (3)	US8247415B2 (pt)
EP (1)	EP2276756B9 (pt)
JP (3)	JP4783867B2 (pt)
KR (3)	KR101331771B1 (pt)
CN (2)	CN102391255B (pt)
AR (1)	AR072043A1 (pt)
AT (1)	ATE535521T1 (pt)
AU (1)	AU2009231714B2 (pt)
BR (1)	BRPI0909768B1 (pt)
CA (1)	CA2719876C (pt)
CL (1)	CL2009000815A1 (pt)
CO (1)	CO6331440A2 (pt)
CR (2)	CR11751A (pt)
CY (1)	CY1112552T1 (pt)
DO (2)	DOP2010000294A (pt)
EA (1)	EA020135B1 (pt)
EC (1)	ECSP10010518A (pt)
ES (1)	ES2376278T3 (pt)
FI (1)	FIC20240046I1 (pt)
FR (1)	FR24C1051I2 (pt)
GE (1)	GEP20125666B (pt)
HN (1)	HN2010002030A (pt)
HR (1)	HRP20120129T2 (pt)
IL (1)	IL208215A (pt)
MA (1)	MA32257B1 (pt)
ME (1)	ME01988B (pt)
MX (1)	MX2010010929A (pt)
NI (1)	NI201000164A (pt)
NL (1)	NL301305I2 (pt)
NO (1)	NO2024055I1 (pt)
NZ (1)	NZ588266A (pt)
PE (1)	PE20091825A1 (pt)
PL (1)	PL2276756T3 (pt)
PT (1)	PT2276756E (pt)
RS (1)	RS52175B (pt)
SG (1)	SG188883A1 (pt)
SI (1)	SI2276756T1 (pt)
SV (1)	SV2010003687A (pt)
TW (1)	TWI378098B (pt)
WO (2)	WO2009124166A1 (pt)
ZA (1)	ZA201006720B (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4891872A (en)	1988-05-09	1990-01-09	Sussman Martin V	Apparatus for incrementally drawing fibers
PE20091825A1 (es) *	2008-04-04	2009-12-04	Merck & Co Inc	Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
IN2012DN00971A (pt) *	2009-08-27	2015-04-10	Merck Sharp & Dohme
JP5738871B2 (ja) *	2009-10-07	2015-06-24	メルク・シャープ・エンド・ドーム・コーポレイション	β３アドレナリン作動性受容体アゴニスト及び抗ムスカリン剤を用いる併用療法
AU2011245499B2 (en) *	2010-04-30	2014-09-25	Merck Sharp & Dohme Corp.	Novel beta 3 adrenergic receptor agonists
CN103140134B (zh) *	2010-07-23	2015-07-29	默沙东公司	新吡咯烷衍生的β3肾上腺素能受体激动剂
AU2011285928B9 (en) *	2010-08-03	2018-08-02	B3Ar Therapeutics, Inc.	Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9522129B2 (en)	2010-08-03	2016-12-20	Velicept Therapeutics, Inc.	Pharmaceutical Combination
US9907767B2 (en)	2010-08-03	2018-03-06	Velicept Therapeutics, Inc.	Pharmaceutical compositions and the treatment of overactive bladder
GB2484713A (en)	2010-10-21	2012-04-25	Optovate Ltd	Illumination apparatus
AU2012293611B2 (en) *	2011-08-11	2017-02-09	Bayer Cropscience Ag	1,2,4-triazolyl-substituted keto-enols
EP2770996B1 (en) *	2011-10-27	2016-09-28	Merck Sharp & Dohme Corp.	Process for making beta 3 agonists and intermediates
ES2584427T3 (es)	2011-10-27	2016-09-27	Merck Sharp & Dohme Corp.	Proceso para la preparación de agonistas beta 3 y productos intermedios
CN104053771B (zh)	2011-11-18	2016-11-09	科德克希思公司	用于制备羟基取代的氨基甲酸酯的生物催化剂
AR089957A1 (es)	2012-02-09	2014-10-01	Altherx Inc	Combinaciones farmaceuticas, combinaciones sinergicas
JP2015178458A (ja) *	2012-07-25	2015-10-08	杏林製薬株式会社	ベンゼン環縮合含窒素５員複素環式化合物、またはその薬理学的に許容される塩
US9784726B2 (en)	2013-01-08	2017-10-10	Atrogi Ab	Screening method, a kit, a method of treatment and a compound for use in a method of treatment
AU2014243818B2 (en)	2013-03-13	2017-04-20	Flatley Discovery Lab, Llc	Pyridazinone compounds and methods for the treatment of cystic fibrosis
HUE045260T2 (hu)	2013-03-15	2019-12-30	Merck Sharp & Dohme	Eljárás béta 3 antagonisták és köztitermékeik elõállítására
CN103232352B (zh) *	2013-05-11	2015-12-23	苏州永健生物医药有限公司	(r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
CN103760286A (zh) *	2014-01-14	2014-04-30	北京万全德众医药生物技术有限公司	一种用高效液相色谱法测定琥珀酸索非那新中间体光学纯度的方法
HRP20210693T1 (hr)	2014-06-11	2021-06-11	VenatoRx Pharmaceuticals, Inc.	Inhibitori beta-laktamaze
EP3226849A4 (en)	2014-12-03	2018-05-09	Velicept Therapeutics, Inc.	Compositions and methods of using modified release solabegron for lower urinary tract symptoms
MX2017009445A (es) *	2015-01-20	2017-11-08	Merck Sharp & Dohme	Inhibidores del factor xia.
US10065922B2 (en)	2015-10-23	2018-09-04	Velicept Therapeutics, Inc.	Solabegron zwitterion and uses thereof
US20170348263A1 (en) *	2016-06-03	2017-12-07	Velicept Therapeutics, Inc.	Compositions and methods of using modified release solabegron for lower urinary tract symptoms
GB201705365D0 (en)	2017-04-03	2017-05-17	Optovate Ltd	Illumination apparatus
GB201705364D0 (en)	2017-04-03	2017-05-17	Optovate Ltd	Illumination apparatus
EP3630783A4 (en)	2017-05-26	2021-03-03	Venatorx Pharmaceuticals, Inc.	PENICILLIN-BINDING PROTEIN INHIBITORS
CN117695287A (zh)	2017-06-06	2024-03-15	住友制药(苏州)有限公司	使用维贝隆以治疗膀胱过度活动症
KR20250095747A (ko)	2017-06-06	2025-06-26	유로반트 사이언시즈 게엠베하	과민성 방광의 치료를 위한 비베그론의 투약
GB201714734D0 (en)	2017-09-13	2017-10-25	Atrogi Ab	New compounds and uses
GB201714740D0 (en)	2017-09-13	2017-10-25	Atrogi Ab	New compounds and uses
GB201714736D0 (en)	2017-09-13	2017-10-25	Atrogi Ab	New compounds and uses
GB201714745D0 (en)	2017-09-13	2017-10-25	Atrogi Ab	New compounds and uses
GB201718307D0 (en)	2017-11-05	2017-12-20	Optovate Ltd	Display apparatus
KR102735800B1 (ko) *	2017-12-21	2024-11-28	교린 세이야쿠 가부시키가이샤	야간빈뇨 치료제
GB201800574D0 (en)	2018-01-14	2018-02-28	Optovate Ltd	Illumination apparatus
GB201803767D0 (en)	2018-03-09	2018-04-25	Optovate Ltd	Illumination apparatus
GB201807747D0 (en)	2018-05-13	2018-06-27	Optovate Ltd	Colour micro-LED display apparatus
CA3098536A1 (en)	2018-05-23	2019-11-28	Urovant Sciences Gmbh	Use of vibegron to treat pain associated with irritable bowel syndrome
EP3802551A4 (en)	2018-05-25	2022-03-02	Venatorx Pharmaceuticals, Inc.	Penicillin-binding protein inhibitors
JP2022510084A (ja) *	2018-12-05	2022-01-26	ウロバントサイエンシズゲーエムベーハー	良性前立腺肥大症の男性の過活動膀胱症状を治療するためのビベグロンの使用
CN109503500A (zh) *	2018-12-17	2019-03-22	天津药明康德新药开发有限公司	一种2-(2-氧代吡嗪-1(2h)-基)乙酸的合成方法
CN109734712B (zh) *	2019-01-30	2020-10-20	广东东阳光药业有限公司	芳基或杂芳基取代的吡咯烷酰胺衍生物及其用途
CA3129024A1 (en)	2019-03-18	2020-09-24	Urovant Sciences Gmbh	Use of vibegron to treat overactive bladder
GB201903832D0 (en)	2019-03-20	2019-05-01	Atrogi Ab	New compounds and methods
EP3994878A4 (en)	2019-07-02	2023-06-14	RealD Spark, LLC	DIRECTIONAL INDICATOR
CN114616498A (zh)	2019-08-23	2022-06-10	瑞尔D斯帕克有限责任公司	定向照明设备和防窥显示器
US11163101B2 (en)	2019-09-11	2021-11-02	Reald Spark, Llc	Switchable illumination apparatus and privacy display
WO2021050967A1 (en)	2019-09-11	2021-03-18	Reald Spark, Llc	Directional illumination apparatus and privacy display
EP4038313A4 (en)	2019-10-03	2023-11-22	RealD Spark, LLC	Illumination apparatus comprising passive optical nanostructures
WO2021067639A1 (en)	2019-10-03	2021-04-08	Reald Spark, Llc	Illumination apparatus comprising passive optical nanostructures
US11287562B2 (en)	2020-02-20	2022-03-29	Reald Spark, Llc	Illumination apparatus including mask with plurality of apertures and display apparatus comprising same
CA3189771A1 (en) *	2020-07-22	2022-01-27	Janssen Pharmaceutica Nv	Compounds useful as factor xia inhibitors
US20240050457A1 (en)	2020-12-22	2024-02-15	Urovant Sciences Gmbh	Methods of monitoring digoxin with concomitant use of vibegron to treat overactive bladder
US20240148735A1 (en)	2021-02-16	2024-05-09	Urovant Sciences Gmbh	Methods of treating heart failure with vibegron
WO2022271582A1 (en)	2021-06-22	2022-12-29	Reald Spark, Llc	Illumination apparatus
GB202113588D0 (en)	2021-09-23	2021-11-10	Atrogi Ab	New compounds and methods
IL314912A (en)	2022-03-02	2024-10-01	Bonafide Health Llc	Preparations and polyglutamic acid and methods of use
GB202205895D0 (en)	2022-04-22	2022-06-08	Atrogi Ab	New medical uses
CN114920771A (zh) *	2022-05-13	2022-08-19	苏州虞美景盛新药开发有限公司	一种用于膀胱过度活动症的口服新药的中间体新合成工艺
CN120187454A (zh) *	2022-10-18	2025-06-20	博纳菲德健康有限公司	β-肾上腺素能激动剂和毒蕈碱性拮抗剂组合物及使用方法
CN115850286B (zh) *	2022-12-05	2023-08-22	奥锐特药业(天津)有限公司	一种维贝格龙中间体及其制备方法
CN117756809A (zh) *	2023-12-21	2024-03-26	苏州莱克施德药业有限公司	(6s)4,6,7,8-四氢-4-氧代吡咯并[1,2-a]嘧啶-6-羧酸甲酯的合成方法
WO2025262600A1 (en)	2024-06-17	2025-12-26	Urovant Sciences Gmbh	Crystalline form of vibegron hemihydrate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6525202B2 (en) *	2000-07-17	2003-02-25	Wyeth	Cyclic amine phenyl beta-3 adrenergic receptor agonists
DOP2003000587A (es) *	2002-02-27	2003-08-30	Pfizer Prod Inc	AGONISTAS DEL RECEPTOR ß3-ADRENERGICO
JP3815496B2 (ja) *	2002-11-07	2006-08-30	アステラス製薬株式会社	酢酸アニリド誘導体を有効成分とする過活動膀胱治療剤
FR2874011B1 (fr) *	2004-08-03	2007-06-15	Sanofi Synthelabo	Derives de sulfonamides, leur preparation et leur application en therapeutique
PE20091825A1 (es)	2008-04-04	2009-12-04	Merck & Co Inc	Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3

2009
- 2009-03-27 PE PE2009000460A patent/PE20091825A1/es active IP Right Grant
- 2009-03-30 AR ARP090101127A patent/AR072043A1/es active IP Right Grant
- 2009-04-02 BR BRPI0909768-6A patent/BRPI0909768B1/pt active IP Right Grant
- 2009-04-02 RS RS20120042A patent/RS52175B/sr unknown
- 2009-04-02 GE GEAP200911992A patent/GEP20125666B/en unknown
- 2009-04-02 PL PL09726601T patent/PL2276756T3/pl unknown
- 2009-04-02 AT AT09726601T patent/ATE535521T1/de active
- 2009-04-02 KR KR1020107024750A patent/KR101331771B1/ko active Active
- 2009-04-02 HR HRP20120129AT patent/HRP20120129T2/hr unknown
- 2009-04-02 CN CN201110265670.2A patent/CN102391255B/zh active Active
- 2009-04-02 NZ NZ588266A patent/NZ588266A/en unknown
- 2009-04-02 WO PCT/US2009/039249 patent/WO2009124166A1/en not_active Ceased
- 2009-04-02 JP JP2010543320A patent/JP4783867B2/ja active Active
- 2009-04-02 CN CN200980121149.2A patent/CN102056917B/zh active Active
- 2009-04-02 SI SI200930188T patent/SI2276756T1/sl unknown
- 2009-04-02 WO PCT/US2009/039253 patent/WO2009124167A1/en not_active Ceased
- 2009-04-02 KR KR1020127026256A patent/KR20120118086A/ko not_active Withdrawn
- 2009-04-02 CA CA2719876A patent/CA2719876C/en active Active
- 2009-04-02 AU AU2009231714A patent/AU2009231714B2/en active Active
- 2009-04-02 PT PT09726601T patent/PT2276756E/pt unknown
- 2009-04-02 US US12/417,239 patent/US8247415B2/en active Active
- 2009-04-02 EA EA201071169A patent/EA020135B1/ru not_active IP Right Cessation
- 2009-04-02 MX MX2010010929A patent/MX2010010929A/es active IP Right Grant
- 2009-04-02 US US12/936,221 patent/US8399480B2/en active Active
- 2009-04-02 KR KR1020127015876A patent/KR101288798B1/ko not_active Expired - Fee Related
- 2009-04-02 ME MEP-2012-549A patent/ME01988B/me unknown
- 2009-04-02 ES ES09726601T patent/ES2376278T3/es active Active
- 2009-04-02 EP EP09726601A patent/EP2276756B9/en active Active
- 2009-04-02 SG SG2013017736A patent/SG188883A1/en unknown
- 2009-04-03 CL CL2009000815A patent/CL2009000815A1/es unknown
- 2009-04-03 TW TW098111302A patent/TWI378098B/zh active
2010
- 2010-07-14 JP JP2010159938A patent/JP5432846B2/ja active Active
- 2010-09-16 IL IL208215A patent/IL208215A/en active IP Right Grant
- 2010-09-20 ZA ZA2010/06720A patent/ZA201006720B/en unknown
- 2010-09-30 SV SV2010003687A patent/SV2010003687A/es unknown
- 2010-09-30 HN HN2010002030A patent/HN2010002030A/es unknown
- 2010-10-01 DO DO2010000294A patent/DOP2010000294A/es unknown
- 2010-10-01 NI NI201000164A patent/NI201000164A/es unknown
- 2010-10-04 CO CO10122821A patent/CO6331440A2/es active IP Right Grant
- 2010-10-04 EC EC2010010518A patent/ECSP10010518A/es unknown
- 2010-10-22 CR CR11751A patent/CR11751A/es unknown
- 2010-10-29 MA MA33292A patent/MA32257B1/fr unknown
2011
- 2011-05-13 JP JP2011107738A patent/JP4783870B1/ja active Active
2012
- 2012-02-29 CY CY20121100209T patent/CY1112552T1/el unknown
- 2012-05-25 CR CR20120282A patent/CR20120282A/es unknown
- 2012-06-20 US US13/527,934 patent/US8653260B2/en active Active
2013
- 2013-11-15 DO DO2013000267A patent/DOP2013000267A/es unknown
2024
- 2024-12-11 NL NL301305C patent/NL301305I2/nl unknown
- 2024-12-12 FR FR24C1051C patent/FR24C1051I2/fr active Active
- 2024-12-12 NO NO2024055C patent/NO2024055I1/no unknown
- 2024-12-16 FI FIC20240046C patent/FIC20240046I1/fi unknown

Also Published As

Publication number	Publication date
US20090253705A1 (en)	2009-10-08
CN102391255B (zh)	2014-07-09
KR101331771B1 (ko)	2013-11-22
US8653260B2 (en)	2014-02-18
WO2009124166A1 (en)	2009-10-08
CA2719876A1 (en)	2009-10-08
IL208215A0 (en)	2010-12-30
CN102056917A (zh)	2011-05-11
MX2010010929A (es)	2010-11-12
NZ588266A (en)	2011-11-25
MA32257B1 (fr)	2011-04-01
FIC20240046I1 (fi)	2024-12-16
CR11751A (es)	2010-11-22
HRP20120129T2 (hr)	2012-09-30
DOP2013000267A (es)	2014-01-31
IL208215A (en)	2014-04-30
BRPI0909768B1 (pt)	2019-01-15
EP2276756B1 (en)	2011-11-30
KR101288798B1 (ko)	2013-07-23
JP2011201897A (ja)	2011-10-13
PL2276756T3 (pl)	2012-04-30
RS52175B (sr)	2012-08-31
US20120258963A1 (en)	2012-10-11
EP2276756A1 (en)	2011-01-26
WO2009124167A1 (en)	2009-10-08
PT2276756E (pt)	2012-02-03
FR24C1051I2 (fr)	2026-01-16
CR20120282A (es)	2012-07-03
US8399480B2 (en)	2013-03-19
FR24C1051I1 (fr)	2025-01-17
ZA201006720B (en)	2011-05-25
SI2276756T1 (sl)	2012-04-30
KR20100126860A (ko)	2010-12-02
AU2009231714B2 (en)	2011-11-03
EA201071169A1 (ru)	2011-04-29
US8247415B2 (en)	2012-08-21
EP2276756B8 (en)	2012-04-11
JP4783870B1 (ja)	2011-09-28
TWI378098B (en)	2012-12-01
HK1147099A1 (en)	2011-07-29
JP2012020961A (ja)	2012-02-02
CN102391255A (zh)	2012-03-28
AU2009231714A1 (en)	2009-10-08
ME01988B (me)	2012-08-31
US20110028481A1 (en)	2011-02-03
JP2011510023A (ja)	2011-03-31
EP2276756B9 (en)	2012-08-15
CL2009000815A1 (es)	2009-08-21
DOP2010000294A (es)	2010-12-31
ATE535521T1 (de)	2011-12-15
CA2719876C (en)	2013-10-01
CO6331440A2 (es)	2011-10-20
TW200944521A (en)	2009-11-01
HRP20120129T1 (hr)	2012-03-31
EA020135B1 (ru)	2014-08-29
NL301305I2 (nl)	2024-12-30
CY1112552T1 (el)	2016-02-10
JP4783867B2 (ja)	2011-09-28
KR20120118086A (ko)	2012-10-25
HN2010002030A (es)	2012-08-13
NI201000164A (es)	2011-06-21
JP5432846B2 (ja)	2014-03-05
ECSP10010518A (es)	2010-11-30
CN102056917B (zh)	2014-11-05
HRP20120129T8 (en)	2012-04-30
AR072043A1 (es)	2010-08-04
SV2010003687A (es)	2011-03-23
NO2024055I1 (no)	2024-12-12
KR20120104257A (ko)	2012-09-20
ES2376278T3 (es)	2012-03-12
GEP20125666B (en)	2012-10-10
SG188883A1 (en)	2013-04-30
PE20091825A1 (es)	2009-12-04

Publication	Publication Date	Title
BRPI0909768A2 (pt)	2015-10-06	composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0917458A2 (pt)	2015-12-01	composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0915382A2 (pt)	2017-06-27	composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0907976A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0819799A2 (pt)	2015-05-26	Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BR112012003464A2 (pt)	2015-09-08	composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio."
BR112012004333A2 (pt)	2015-09-08	composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0913585A2 (pt)	2015-10-27	composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI1013984A2 (pt)	2018-06-19	composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI0821299A2 (pt)	2015-06-16	Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
CL2007003049A1 (es)	2008-05-16	Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0906786A2 (pt)	2015-07-14	Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.
BRPI0814957A2 (pt)	2015-02-03	Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto.
BRPI0820568A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal
BRPI0907974A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0819755A2 (pt)	2018-07-17	composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI0815708A2 (pt)	2014-09-30	Composto, éster de pró-droga, composição farmacêutica, e, método para tratar uma doença ou condição.
BRPI1013763A2 (pt)	2015-08-25	Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto
BRPI0915084A2 (pt)	2015-10-27	composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BRPI0922475A2 (pt)	2017-06-06	composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.

Legal Events

Date	Code	Title	Description
2016-01-26	B25A	Requested transfer of rights approved	Owner name: SCHERING CORPORATION (UY)
2016-02-10	B25D	Requested change of name of applicant approved	Owner name: MERCK SHARP AND DOHME CORP. (US)
2016-02-23	B25G	Requested change of headquarter approved	Owner name: MERCK SHARP AND DOHME CORP. (US)
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-04-24	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2018-05-22	B06I	Publication of requirement cancelled [chapter 6.9 patent gazette]
2018-06-05	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2018-11-06	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-01-15	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/04/2009, OBSERVADAS AS CONDICOES LEGAIS.